

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau**B8**

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/82, 15/31, A01H 5/00	A1	(11) International Publication Number: WO 99/10514 (43) International Publication Date: 4 March 1999 (04.03.99)
(21) International Application Number: PCT/US98/17546 (22) International Filing Date: 25 August 1998 (25.08.98) (30) Priority Data: 60/057,562 26 August 1997 (26.08.97) US (71) Applicant (for all designated States except US): NORTH CAROLINA STATE UNIVERSITY [US/US]; 1 Holladay Hall, Campus Box 7003, Raleigh, NC 27695-7003 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): OBEID, Lina, M. [US/US]; 104 Crowther Court, Chapel Hill, NC 27514 (US). BOSS, Wendy, F. [US/US]; 8621 Carswell Court, Raleigh, NC 27613 (US). MAO, Cungui [CN/US]; 941 Lambeth Circle, 18B, Durham, NC 27705 (US). (74) Agents: BENNETT, Virginia, C. et al.; Myers, Bigel, Sibley, & Sajovec, P.A., P.O. Box 37428, Raleigh, NC 27627 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: FUMONOSIN RESISTANCE (57) Abstract DNA encoding a protein capable of increasing resistance to mycotoxins of the fumonosin family is described, as are gene transfer vectors useful for imparting fumonosin resistance (e.g., resistance to fumonosin B1) to a plant or animal. The vector comprises an expression cassette, the expression cassette contains a DNA encoding a fumonosin-resistance protein. Methods of making fumonosin-resistant transgenic plants and animals, and fumonosin-resistant transgenic plants and animals, are also described.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

FUMONOSIN RESISTANCE

This application claims the benefit of U.S. Provisional Application No. 60/057,562; filed 26 August 1997.

This invention was made with Government support under grant number IR29-AG-12467 from the National Institutes of Health. The Government has
5 certain rights to this invention.

Field of the Invention

The present invention relates to DNA encoding proteins that increase resistance to the mycotoxin fumonisin in plant and animal cells, and to
10 transgenic plants and animals having increased resistance to mycotoxins of the fumonisin family, such as fumonisin B1.

Background of the Invention

The fumonisins are a family of mycotoxins that are common
15 contaminants of maize, sorghum and related grains throughout the world. These compounds were first identified in a study of a high incidence of oesophageal cancer in certain villagers in the Transkei region of South Africa. The villagers consumed beer brewed from moldy corn infected by *Fusarium moniliforme*, which produces fumonisin B1. A. Merrill et al., *Trends in Cell Biology* 6, 218
20 (June 1996).

Fumonisin B1, the most common of the fumonosins, is produced by *F. moniliforme* (Sheldon). The toxin is also implicated in two devastating and costly diseases of veterinary animals: equine leukoencephalomacina and porcine pulmonary oedema. *Id.* Fumonisin B1 is both toxic and carcinogenic to plants and animals.

In view of the foregoing, it would be extremely useful to have a means for imparting fumonosin resistance to plants, particularly grains and other monocots, as well as plants and animals susceptible to infection with a fumonosin-producing fungi.

Summary of the Invention

A first aspect of the present invention is a plant or animal gene transfer vector useful for imparting fumonosin resistance to a plant or animal. The vector comprising an expression cassette, the expression cassette contains a DNA encoding a fumonosin-resistance protein (*e.g.*, an ATP-binding cassette transporter). In general, such a DNA is (a) a DNA having a sequence according to SEQ ID NO:1, (b) a DNA that hybridizes to DNA having a sequence according to SEQ ID NO:1 and encodes an ATP-binding cassette transporter that imparts fumonosin-resistance to a plant or animal cell, or (c) a DNA that encodes a protein encoded by a DNA of (a) or (b) above, but differs from the DNA of (a) or (b) above due to the degeneracy of the genetic code.

A second aspect of the present invention is a method of making a fumonosin-resistant transgenic plant. The method comprises transforming a plant cell with an expression cassette as described above, and then regenerating a fumonosin-resistant transgenic plant from the transformed plant cell.

A third aspect of the present invention is a fumonosin-resistant transgenic plant, wherein some or all of the cells of the plant contain a heterologous expression cassette as described above.

A fourth aspect of the present invention is a method of making a fumonosin-resistant transgenic animal. The method comprises transforming an

animal cell with an expression cassette as described above, and then regenerating a fumonosin-resistant transgenic animal from the transformed animal cell.

A fifth aspect of the present invention is a fumonosin-resistant transgenic non-human animal, wherein some or all of the cells of the animal containing a
5 heterologous expression cassette as described above.

The foregoing and other objects and aspects of the present invention are explained in greater detail in the specification set forth below.

Detailed Description of the Invention

10 The present invention may be used to impart resistance to any type of fumonosin to plants and animals, including fumonosins of the A, B, and C series (e.g., fumonosin A1, fumonosin B1, fumonosin B2, fumonosin C1, phytotoxin TA). The imparting of resistance to B series fumonosins is preferred, and the imparting of resistance to fumonosin B1 is most preferred. The term "resistance" as used
15 herein does not imply complete resistance, but rather refers to any increase in the level of resistance that is of a commercial agricultural or veterinary advantage as compared to the same animal without the presence of the expression cassette.

A. DNA sequences

20 DNAs sequences useful for carrying out the present invention include those coding for ATP-binding cassette (ABC) transporters, and particularly for proteins homologous to, and having essentially the same biological properties as, the protein given herein SEQ ID NO:2. This definition is intended to encompass natural allelic variations therein. Isolated DNA or cloned genes of the present invention
25 can be of any species of origin, including microorganism, plant, and animal, (see generally C. Higgins, ABC Transporters: from microorganisms to man, *Annu. Rev. Cell Biol.* 8: 67 (1992)), but are typically of natural origin and are preferably of yeast origin. Thus, DNAs which hybridize to DNA disclosed herein as SEQ ID NO:1 (or fragments or derivatives thereof which serve as hybridization probes as
30 discussed below) and which code on expression for a protein of the present

invention (e.g., a protein according to SEQ ID NO:2) are also an aspect of this invention.

Conditions which will permit other DNAs which code on expression for a protein of the present invention to hybridize to the DNA of SEQ ID NO:1 disclosed herein can be determined in accordance with known techniques. For example, hybridization of such sequences may be carried out under conditions of reduced stringency, medium stringency or even stringent conditions (e.g., conditions represented by a wash stringency of 35-40% Formamide with 5x Denhardt's solution, 0.5% SDS and 1x SSPE at 37°C; conditions represented by a wash stringency of 40-45% Formamide with 5x Denhardt's solution, 0.5% SDS, and 1x SSPE at 42°C; and conditions represented by a wash stringency of 50% Formamide with 5x Denhardt's solution, 0.5% SDS and 1x SSPE at 42°C, respectively) to DNA of SEQ ID NO:1 disclosed herein in a standard hybridization assay. *See, e.g.*, J. Sambrook et al., Molecular Cloning, A Laboratory Manual (2d Ed. 1989)(Cold Spring Harbor Laboratory)). In general, sequences which code for proteins of the present invention and which hybridize to the DNA of SEQ ID NO:1 disclosed herein will be at least 75% homologous, 85% homologous, and even 95% homologous or more with SEQ ID NO:1.

DNAs which code for proteins of the present invention, or DNAs which hybridize to that of SEQ ID NO:1, but which differ in codon sequence from SEQ ID NO:1 due to the degeneracy of the genetic code, are also an aspect of this invention. The degeneracy of the genetic code, which allows different nucleic acid sequences to code for the same protein or peptide, is well known in the literature. *See, e.g.*, U.S. Patent No. 4,757,006 to Toole et al. at Col. 2, Table 1.

Knowledge of the nucleotide sequence as disclosed herein in SEQ ID NO:1 can be used to generate hybridization probes which specifically bind to the DNA of the present invention or to mRNA to determine the presence of amplification or overexpression of the proteins of the present invention. Pairs of probes which will serve as PCR primers for the DNA sequences of the present invention, or portions thereof, may be used in accordance with the process described in U.S. Patents Nos. 4,683,202 and 4,683,195 to Mullis (applicant specifically intends that the

disclosures of all U.S. Patent references disclosed herein be incorporated herein by reference).

Since numerous ATP-binding cassette (ABC) transporters are known, *see, e.g., C. Higgins, Annu. Rev. Cell Biol.* 8, 67 (1992), ABC transporters that impart
5 fumonisin resistance to plant or animal cells when expressed therein can also be identified by expressing that transporter in a plant or animal cell, or a yeast cell, and then testing that cell for fumonisin resistance, essentially as described below.

B. Genetic Engineering Techniques

10 The production of cloned genes, recombinant DNA, vectors, transformed host cells, proteins and protein fragments by genetic engineering is well known. *See, e.g., U.S. Patent No. 4,761,371 to Bell et al. at Col. 6 line 3 to Col. 9 line 65; U.S. Patent No. 4,877,729 to Clark et al. at Col. 4 line 38 to Col. 7 line 6; U.S. Patent No. 4,912,038 to Schilling at Col. 3 line 26 to Col. 14 line 12; and U.S.*
15 *Patent No. 4,879,224 to Wallner at Col. 6 line 8 to Col. 8 line 59. (Applicant specifically intends that the disclosure of all U.S. patent references cited herein be incorporated by reference herein in their entirety).*

DNA constructs of the present invention may be used to transform cells from a variety of organisms, including plants (*i.e., vascular plants*) and animals
20 (particularly mammals such as horses, cows and pigs). As used herein, plants includes both gymnosperms and angiosperms (*i.e., monocots and dicots*). Transformation according to the present invention may be used to increase expression levels of transgenes in stably transformed cells.

The term "operatively associated," as used herein, refers to DNA sequences
25 on a single DNA molecule which are associated so that the function of one is affected by the other. Thus, a transcription initiation region is operatively associated with a structural gene when it is capable of affecting the expression of that structural gene (*i.e., the structural gene is under the transcriptional control of the transcription initiation region*). The transcription initiation region is said to be
30 "upstream" from the structural gene, which is in turn said to be "downstream" from the transcription initiation region.

DNA constructs, or "expression cassettes," of the present invention preferably include, 5' to 3' in the direction of transcription, a transcription initiation region, a structural gene operatively associated with the transcription initiation region, and a termination sequence including a stop signal for RNA polymerase and a polyadenylation signal for polyadenylation (e.g., the nos terminator. All of these regions should be capable of operating in the cells to be transformed. Matrix attachment regions flanking the expression cassette may optionally be included. The termination region may be derived from the same gene as the transcription initiation or promoter region, or may be derived from a different gene.

10 The transcription initiation region, which preferably includes the RNA polymerase binding site (promoter), may be native to the host organism to be transformed or may be derived from an alternative source, where the region is functional in the host. Other sources include the *Agrobacterium* T-DNA genes, such as the transcriptional initiation regions for the biosynthesis of nopaline, octapine, mannopine, or other opine transcriptional initiation regions, transcriptional initiation regions from plants, transcriptional initiation regions from viruses (including host specific viruses), or partially or wholly synthetic transcription initiation regions. Transcriptional initiation and termination regions are well known. See, e.g., dGreve, *J. Mol. Appl. Genet.* 1, 499-511 (1983); Salomon et al., *EMBO J.* 3, 141-146 (1984); Garfinkel et al., *Cell* 27, 143-153 (1983); and Barker et al., *Plant Mol. Biol.* 2, 235-350 (1983).

25 The transcriptional initiation regions may, in addition to the RNA polymerase binding site, include regions which regulate transcription, where the regulation involves, for example, chemical or physical repression or induction (e.g., regulation based on metabolites or light) or regulation based on cell differentiation (such as associated with leaves, roots, seed, or the like in plants). Thus, the transcriptional initiation region, or the regulatory portion of such region, is obtained from an appropriate gene which is so regulated. For example, the 1,5-ribulose biphosphate carboxylase gene is light-induced and may be used for transcriptional initiation. Other genes are known which are induced by stress, temperature, wounding, pathogen effects, etc. Tissue specific promoters, such as

root-specific promoters or a promoter specific for corn silk, may advantageously be employed as will be apparent to those skilled in the art. In corn for the prevention of corn ear rot (or "pink ear rot of maize"), a promoter associated with Pedicel Glutamine Synthetase gene (preferentially expressed in the region of the kernel attached to the cob, where fumonisin-fungi enter the kernel) may be employed, or a promoter that preferentially expresses in the seed or seed coat.

The expression cassette may be provided in a DNA construct that also has at least one replication system. For convenience, it is common to have a replication system functional in *Escherichia coli*, such as ColE1, pSC101, pACYC184, or the like. In this manner, at each stage after each manipulation, the resulting construct may be cloned, sequenced, and the correctness of the manipulation determined. In addition, or in place of the *E. coli* replication system, a broad host range replication system may be employed, such as the replication systems of the P-1 incompatibility plasmids, e.g., pRK290. In addition to the replication system, there will frequently be at least one marker present, which may be useful in one or more hosts, or different markers for individual hosts. That is, one marker may be employed for selection in a prokaryotic host, while another marker may be employed for selection in a eukaryotic host, particularly a plant host. The markers may be protection against a biocide, such as antibiotics, toxins, heavy metals, or the like; provide complementation, for example by imparting prototrophy to an auxotrophic host; or provide a visible phenotype through the production of a novel compound. Exemplary genes that may be employed include neomycin phosphotransferase (NPTII), hygromycin phosphotransferase (HPT), chloramphenicol acetyltransferase (CAT), nitrilase, and the gentamicin resistance gene. For plant host selection, non-limiting examples of suitable markers are β -glucuronidase, providing indigo production, luciferase, providing visible light production, NPTII, providing kanamycin resistance or G418 resistance, HPT, providing hygromycin resistance, and the mutated *aroA* gene, providing glyphosate resistance.

The various fragments comprising the various constructs, expression cassettes, markers, and the like may be introduced consecutively by restriction enzyme cleavage of an appropriate replication system, and insertion of the

particular construct or fragment into the available site. After ligation and cloning the DNA construct may be isolated for further manipulation. All of these techniques are amply exemplified in the literature and find particular exemplification in Sambrook et al., Molecular Cloning: A Laboratory Manual, (2d Ed. 1989)(Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).

C. Plant Genetic Engineering

As noted above, the present invention provides a method of making a fumonosin-resistant transgenic plant. The term "plant" as used herein refers to vascular plants (e.g., gymnosperms and angiosperms). The method comprises transforming a plant cell with an expression cassette as described above, and then regenerating a fumonosin-resistant transgenic plant from the transformed plant cell. The transforming step may be carried out by any suitable means, including by *Agrobacterium*-mediated transformation and non-*Agrobacterium*-mediated transformation, as discussed in detail below. Plants are regenerated from the transformed cell (or cells) by techniques known to those skilled in the art, as also discussed below. Where chimeric plants are produced by the process, plants in which all cells are transformed may be regenerated from chimeric plants having transformed germ cells, as is known in the art.

Vectors that may be used to transform plant tissue with DNA constructs/expression cassettes of the present invention include both *Agrobacterium* and non-*Agrobacterium* vectors, particularly ballistic vectors, as well as vectors suitable for DNA-mediated transformation.

***Agrobacterium* mediated transformation.** *Agrobacterium*-mediated gene transfer exploits the natural ability of *Agrobacterium tumefaciens* to transfer DNA into plant chromosomes. *Agrobacterium* is a plant pathogen that transfers a set of genes encoded in a region called T-DNA of the Ti plasmid into plant cells at wound sites. The typical result of gene transfer is a tumorous growth called a crown gall in which the T-DNA is stably integrated into a host chromosome. The ability to cause crown gall disease can be removed by deletion of the genes in the T-DNA without loss of DNA transfer and integration. The DNA to be

transferred is attached to border sequences that define the end points of an integrated T-DNA.

The *Agrobacterium* strain utilized in the methods of the present invention is modified to contain a gene or genes of interest, or a nucleic acid to be expressed in the transformed cells. The nucleic acid to be transferred is incorporated into the T-region and is flanked by T-DNA border sequences. A variety of *Agrobacterium* species are known in the art particularly for dicotyledon transformation. Such *Agrobacterium* can be used in the methods of the invention. See, e.g., Hooykaas, *Plant Mol. Biol.* 13, 327 (1989); Smith et al., *Crop Science* 35, 301 (1995); Chilton, *Proc. Natl. Acad. Sci. USA* 90, 3119 (1993); Mollony et al., *Monograph Theor. Appl. Genet NY* 19, 148 (1993); Ishida et al., *Nature Biotechnol.* 14, 745 (1996); and Komari et al., *The Plant Journal* 10, 165 (1996), the disclosures of which are incorporated herein by reference.

In addition to the T-region, the Ti plasmid contains a *vir* region. The *vir* region is important for efficient transformation, and appears to be species-specific. Binary vector systems have been developed where the manipulated disarmed T-DNA carrying foreign DNA and the *vir* functions are present on separate plasmids. In this manner, a modified T-DNA region comprising foreign DNA (the nucleic acid to be transferred) is constructed in a small plasmid which replicates in *E. coli*. This plasmid is transferred conjugatively in a tri-parental mating into *Agrobacterium tumefaciens* that contains a compatible plasmid-carrying virulence gene. The *vir* functions are supplied in *trans* to transfer the T-DNA into the plant genome. Such binary vectors are useful in the practice of the present invention.

Preferred vectors of the present invention are super-binary vectors. See, e.g., United States Patent No. 5,591,615 and EP 0 604 662. Such a super-binary vector has been constructed containing a DNA region originating from the virulence region of the Ti plasmid pTiBo542 (Jin et al., *J. Bacteriol.* 169, 4417 (1987)) contained in a super-virulent *Agrobacterium tumefaciens* A281 exhibiting extremely high transformation efficiency (Hood et al., *Biotechnol.* 2, 702 (1984);

Hood et al., *J. Bacteriol.* 168, 1283 (1986); Komari et al., *J. Bacteriol.* 166, 88 (1986); Jin et al., *J. Bacteriol.* 169, 4417 (1987); Komari, *Plant Science* 60, 223 (1987); ATCC Accession No. 37394. Exemplary super-binary vectors known to those skilled in the art include pTOK162 (Japanese patent Appl. (Kokai) No. 4-222527, EP 504,869, EP 604,662, and United States Patent No. 5,591,616, herein incorporated by reference) and pTOK233 (Komari, *Plant Cell Reports* 9,303 (1990); Ishida et al., *Nature Biotechnology* 14, 745 (1996); herein incorporated by reference). Other super-binary vectors may be constructed by the methods set forth in the above references. Super-binary vector pTOK162 is capable of replication in both *E. coli* and in *A. tumefaciens*. Additionally, the vector contains the *virB*, *virC* and *virG* genes from the virulence region of pTiBo542. The plasmid also contains an antibiotic resistance gene, a selectable marker gene, and the nucleic acid of interest to be transformed into the plant. The nucleic acid to be inserted into the sorghum genome is located between the two border sequences of the T region. Super-binary vectors of the invention can be constructed having the features described above for pTOK162. The T-region of the super-binary vectors and other vectors for use in the invention are constructed to have restriction sites for the insertion of the genes to be delivered. Alternatively, the DNA to be transformed can be inserted in the T-DNA region of the vector by utilizing *in vivo* homologous recombination. See, Herrera-Esterella et al., *EMBO J.* 2, 987 (1983); Horsch et al., *Science* 223, 496 (1984). Such homologous recombination relies on the fact that the super-binary vector has a region homologous with a region of pBR322 or other similar plasmids. Thus, when the two plasmids are brought together, a desired gene is inserted into the super-binary vector by genetic recombination via the homologous regions.

Non-Agrobacterium mediated transformation. Microparticles carrying a DNA construct of the present invention, which microparticles are suitable for the ballistic transformation of a cell, are also useful as a vector for transforming cells according to the present invention. The microparticle is propelled into a cell to produce a transformed cell. Where the transformed cell is a plant cell, a plant may be regenerated from the transformed cell according to techniques known in the art.

Any suitable ballistic cell transformation methodology and apparatus can be used in practicing the present invention. Exemplary apparatus and procedures are disclosed in Sanford and Wolf, U.S. Patent No. 4,945,050. When using ballistic transformation procedures, the expression cassette may be incorporated into a plasmid capable of replicating in the cell to be transformed. Examples of microparticles suitable for use in such systems include 1 to 5 μ m gold spheres. The DNA construct may be deposited on the microparticle by any suitable technique, such as by precipitation.

Plant species may be transformed with the DNA construct of the present invention by the DNA-mediated transformation of plant cell protoplasts and subsequent regeneration of the plant from the transformed protoplasts in accordance with procedures well known in the art.

Any plant tissue capable of subsequent clonal propagation, whether by organogenesis or embryogenesis, may be transformed with a vector of the present invention. The term "organogenesis," as used herein, means a process by which shoots and roots are developed sequentially from meristematic centers; the term "embryogenesis," as used herein, means a process by which shoots and roots develop together in a concerted fashion (not sequentially), whether from somatic cells or gametes. The particular tissue chosen will vary depending on the clonal propagation systems available for, and best suited to, the particular species being transformed. Exemplary tissue targets include leaf disks, pollen, embryos, cotyledons, hypocotyls, megagametophytes, callus tissue, existing meristematic tissue (e.g., apical meristems, axillary buds, and root meristems), and induced meristem tissue (e.g., cotyledon meristem and hypocotyl meristem).

Plants of the present invention may take a variety of forms. The plants may be chimeras of transformed cells and non-transformed cells; the plants may be clonal transformants (e.g., all cells transformed to contain the expression cassette); the plants may comprise grafts of transformed and untransformed tissues (e.g., a transformed root stock grafted to an untransformed scion in citrus species). The transformed plants may be propagated by a variety of means, such as by clonal propagation or classical breeding techniques. For example, first generation (or T1)

transformed plants may be selfed to give homozygous second generation (or T2) transformed plants, and the T2 plants further propagated through classical breeding techniques. A dominant selectable marker (such as *npt II*) can be associated with the expression cassette to assist in breeding.

5 Plants that may be employed in practicing the present invention include (but are not limited to) maize or corn (*Zea mays*), sorghum, wheat, oats, rye, barley, rice, tobacco (*Nicotiana tabacum*), potato (*Solanum tuberosum*), soybean (*glycine max*), peanuts (*Arachis hypogaea*), cotton (*Gossypium hirsutum*), sweet potato (*Ipomoea batatas*), cassava (*Manihot esculenta*), coffee (*Cofea* spp.), coconut
10 (*Cocos nucifera*), pineapple (*Ananas comosus*), citrus trees (*Citrus* spp.), cocoa (*Theobroma cacao*), tea (*Camellia sinensis*), banana (*Musa* spp.), avocado (*Persea americana*), fig (*Ficus casica*), guava (*Psidium guajava*), mango (*Mangifera indica*), olive (*Olea europaea*), papaya (*Carica papaya*), cashew (*Anacardium occidentale*), macadamia (*Macadamia integrifolia*), almond (*Prunus amygdalus*),
15 sugar beets (*Beta vulgaris*), vegetables, ornamentals, and conifers.

Particularly preferred plants for carrying out the present invention are maize (*Zea mays*) and sorghum.

D. Transgenic Animals.

20 A method of making a fumonosin-resistant transgenic animal is also an aspect of the present invention. The method can be carried out on any suitable animal subject, but is preferably carried out with non-human mammals. Ovine, bovine, and equine species are particularly preferred (e.g., pigs, cows, and horses).

The method comprises transforming an animal cell with an expression
25 cassette as described above, in an animal transformation vector, and then regenerating a fumonosin-resistant transgenic animal from the transformed animal cell. The transformation step may be carried out by any suitable means, as discussed in detail below, and the regeneration step may also be carried out by any suitable means, as also discussed in detail below. Where chimeric animals
30 are produced by the process, animals in which all cells are transformed may be

regenerated from chimeric animals having transformed germ cells, as is known in the art.

The production of transgenic animals can be carried out by any suitable technique, such as pronuclear microinjection, infection of embryos with retroviruses, embryonic stem cell-mediated techniques, transfer of entire chromosomal segments and gamete transfection in conjunction with *in vitro* fertilization, etc. See generally Charles River Laboratories, *Transgenic Animal Science: Principles and Methods* (Summer 1991).

Transgenic animals that express an ABC transporter protein can be produced by the genetic transformation of zygotes, as described in T. Wagner et al., U.S. Patent No. 4,873,191 (applicant intends that the disclosure of all U.S. Patent References cited herein be incorporated herein by reference).

Methods of producing a transgenic bovine or transgenic bovine embryo are described in U.S. Patent No. 5,663,076 to H. DeBoer et al.

In another technique, a pluripotent embryonic stem cell from the species to be transformed may be derived, the expression cassette inserted into the stem cell, and one or more of the stem cells inserted into an early embryo such as a blastocyst of the animal to be transformed, and the animal raised to birth in a suitable female host (e.g., M. Evans, PCT Application WO90/03432).

In still another technique, embryonic stem cells useful for making chimeric and transgenic ungulates (e.g., porcine, bovine, ovine and caprine species) are described in M. Wheeler, PCT Application WO 94/26884. In general, the embryonic stem cells are transformed with the exogenous genetic material of interest (e.g., an ABC transporter expression cassette) and then used to provide chimeric ungulates which have germ cells comprising the exogenous genetic material. The chimeric ungulates are bred to provide transgenic ungulates (see also U.S. Patent No. 5,523,226 to M. Wheeler).

Methods of producing transgenic animals by subjecting a mixture of DNA and the embryo to an electric discharge are described in U.S. Patent No. 5,567,607 to X. Zhao et al.

Mammalian expression vectors are described in U.S. Patent No. 5,627,033 to J. Smith et al.

E. Utilities

5 The methods, constructs, and products described above are useful in providing a selectable marker (*i.e.*, Fumonisin resistance) for genetic engineering techniques, where other nucleic acid segments are being introduced into the plant or animal cell in association with the fumonisin-resistance gene.

10 The methods, constructs, and products described above are useful in providing plants and animals that are resistant, or have greater levels of resistance, to naturally occurring fumonisin infection.

 The examples that follow are provided to illustrate the present invention, and are not to be construed as limiting thereof.

15

EXPERIMENTAL

 A Fumonisin B1 sensitive *Sacharomyces cerevisiae* strain (JS16) was screened, which was sensitive to 400 μ M Fumonisin B1 in synthetic complete medium at a cell density as high as 10^7 cells/mL (Wild-type yeast strain JK93da is resistant to as high as 1 mM Fumonisin B1). Then, a *S. cerevisiae* genomic DNA library was constructed in the multicopy vector YEP24. JS16 was transformed with the DNA library and four Fumonisin B1 resistant clones were selected on synthetic complete agar medium with 400 μ M Fumonisin B1.

25 DNA sequencing was carried out among the four clones. Two of them had the same DNA sequence, the other two had the consensus DNA sequences as the first two clones. The consensus sequence (SEQ ID NO:1) encodes a protein of 1477 amino acid residues (SEQ ID NO:2). Overexpression of the protein confers Fumonisin B1 resistance to *S. cerevisiae*.

30 The gene deletion mutant is sensitive to Fumonisin B1 compared to wild type strain (JK93da).

A yeast database was searched. It was found that the protein belongs to an ABC transport family. See D. Katzmman et al., *Molecular and Cellular Biology* 15, 6875 (1995). The gene is located on chromosome VII.

That which is claimed is:

1. A DNA construct comprising an expression cassette, which construct comprises, in the 5' to 3' direction, a promoter operable in a plant cell and a DNA segment according to claim 1 positioned downstream from said promoter and operatively associated therewith, said DNA segment selected from
5 the group consisting of:

(a) SEQ ID NO:1;

(b) DNA sequences which encode an enzyme having SEQ ID NO:2;

10 (c) DNA sequences which hybridize to isolated DNA of (a) or (b) above and which encode an ATP-binding cassette transporter; and

(d) DNA sequences which differ from the DNA of (a), (b) or (c) above due to the degeneracy of the genetic code.

2. A DNA construct according to claim 1, wherein said promoter is constitutively active in plant cells.

3. A DNA construct according to claim 1, wherein said promoter is selectively active in plant tissue cells.

4. A DNA construct according to claim 3, wherein said promoter is selectively active in plant cells selected from root cells, seed cells, seed coat cells, and corn silk cells.

5. A DNA construct according to claim 3, wherein said promoter is a corn Pedicel Glutamine Synthetase promoter that is expressed in the region of the corn kernel attached to the cob.

6. A DNA construct according to claim 1, wherein said construct further comprises a plasmid.

7. A DNA construct according to claim 1 carried by a plant transformation vector.

8. A DNA construct according to claim 1 carried by a plant transformation vector, which plant transformation vector is an *Agrobacterium tumefaciens* vector.

9. A plant cell containing a DNA construct according to claim 1.

10. A transgenic plant comprising plant cells according to claim 9.

11. A method of making a transgenic plant cell having increased resistance to fumonosin, said method comprising:

providing a plant cell;

providing an exogenous DNA construct, which construct comprises,
5 in the 5' to 3' direction, a promoter operable in a plant cell and a DNA sequence that encodes an ATP-binding cassette transporter protein that increases resistance of a plant cell to fumonosin, said DNA sequence operably associated with said promoter; and

transforming said plant cell with said DNA construct to produce a
10 transformed plant cell, said plant cell having increased resistance to fumonosin compared to an untransformed cell.

12. The method of claim 11, wherein said plant cell is a corn cell.

13. The method of claim 11, further comprising regenerating a plant from said transformed plant cell.

14. A method according to claim 11, wherein said promoter is constitutively active.

15. A method according to claim 11, wherein said promoter is selectively active in plant cells.

16. A method according to claim 11, wherein said promoter is selectively active in plant cells selected from root cells, seed cells, seed coat cells, and corn silk cells.

17. A method according to claim 11, wherein said promoter is a corn Pedicel Glutamine Synthetase promoter that is expressed in the region of the corn kernel attached to the cob.

18. A method according to claim 11, wherein said transforming step is carried out by bombarding said plant cell with microparticles carrying said DNA construct.

19. A method according to claim 11 wherein said transforming step is carried out by infecting said plant cell with an *Agrobacterium tumefaciens* containing a Ti plasmid carrying said DNA construct.

20. A method of producing transgenic plant seeds, comprising collecting seed from a transgenic plant produced by the method of claim 11.

21. The method according to claim 11, wherein said exogenous DNA sequence comprises a DNA sequence selected from the DNA sequences of Claim 1.

22. A transgenic plant having increased resistance to fumonosin compared to a non-transformed control plant, said transgenic plant comprising transgenic plant cells containing:

an exogenous DNA construct comprising, in the 5' to 3' direction, a promoter operable in said plant cell and a DNA sequence that encodes an ATP-binding cassette transporter protein that increases resistance of a plant cell to fumonosin, said DNA sequence operably associated with said promoter;

5 said plant exhibiting increased fumonosin resistance compared to a non-transformed control plant.

23. The method according to claim 22, wherein said exogenous DNA sequence comprises a DNA sequence selected from the DNA sequences of claim 1.

24. A plant according to claim 22, wherein said promoter is a constitutively active promoter.

25. A plant according to claim 22, wherein said promoter is selectively active in plant cells.

26. A method according to claim 22, wherein said promoter is selectively active in plant cells selected from root cells, seed cells, seed coat cells, and corn silk cells.

27. A method according to claim 22, wherein said promoter is a corn Pedicel Glutamine Synthetase promoter that is expressed in the region of the corn kernel attached to the cob.

28. A transgenic plant according to claim 22, which plant is corn.

29. A transgenic corn plant having increased fumonosin resistance compared to a non-transformed control plant, wherein said transgenic plant is a progeny of a plant according to claim 28.

30. Seeds of a transgenic corn plant having increased fumonosin resistance relative to a non-transformed control plant, wherein said transgenic plant is a plant according to claim 28 or a progeny thereof.

31. A method of producing transgenic plant seeds, comprising collecting seed from a transgenic plant produced by the method of claim 22.

1
SEQUENCE LISTING

<110> Obeid, Lina M.

Boss, Wendy F.

Mao, Cungui

<120> Fumonisin Resistance Proteins

<130> Obeid et al.

<140>

<141>

<150> 60/057,562

<151> 1997-08-26

<160> 2

<170> PatentIn Ver. 2.0

<210> 1

<211> 4434

<212> DNA

<213> *Saccharomyces cerevisiae*

<220>

<221> CDS

<222> (1) .. (4434)

2

<400> 1

atg acg att acc gtg ggg gat gca gtt tcg gag acg gag ctg gaa aac 48
 Met Thr Ile Thr Val Gly Asp Ala Val Ser Glu Thr Glu Leu Glu Asn
 1 5 10 15

aaa agt caa aac gtg gta cta tct ccc aag gca tct gct tct tca gac 96
 Lys Ser Gln Asn Val Val Leu Ser Pro Lys Ala Ser Ala Ser Ser Asp
 20 25 30

ata agc aca gat gtt gat aag gac aca tcg tct tct tgg gat gac aaa 144
 Ile Ser Thr Asp Val Asp Lys Asp Thr Ser Ser Ser Trp Asp Asp Lys
 35 40 45

tct ttg ctg cct aca ggt gaa tat att gtg gac aga aat aag ccc caa 192
 Ser Leu Leu Pro Thr Gly Glu Tyr Ile Val Asp Arg Asn Lys Pro Gln
 50 55 60

acc tac ttg aat agc gat gat atc gaa aaa gtg aca gaa tct gat att 240
 Thr Tyr Leu Asn Ser Asp Asp Ile Glu Lys Val Thr Glu Ser Asp Ile
 65 70 75 80

ttc cct cag aaa cgt ctg ttt tca ttc ttg cac tct aag aaa att cca 288
 Phe Pro Gln Lys Arg Leu Phe Ser Phe Leu His Ser Lys Lys Ile Pro
 85 90 95

gaa gta cca caa acc gat gac gag agg aag ata tat cct ctg ttc cat 336
 Glu Val Pro Gln Thr Asp Asp Glu Arg Lys Ile Tyr Pro Leu Phe His
 100 105 110

3

aca aat att atc tct aac atg ttt ttt tgg tgg gtt cta ccc atc ctg 384

Thr Asn Ile Ile Ser Asn Met Phe Phe Trp Trp Val Leu Pro Ile Leu

115

120

125

cga gtt ggt tat aag aga acg ata cag ccg aac gat ctc ttc aaa atg 432

Arg Val Gly Tyr Lys Arg Thr Ile Gln Pro Asn Asp Leu Phe Lys Met

130

135

140

gat ccg agg atg tct ata gag acc ctt tat gac gac ttt gaa aaa aac 480

Asp Pro Arg Met Ser Ile Glu Thr Leu Tyr Asp Asp Phe Glu Lys Asn

145

150

155

160

atg att tac tat ttt gag aag acg agg aaa aaa tac cgt aaa aga cat 528

Met Ile Tyr Tyr Phe Glu Lys Thr Arg Lys Lys Tyr Arg Lys Arg His

165

170

175

cca gaa gcg aca gaa gaa gag gtt atg gaa aat gcc aaa cta cct aaa 576

Pro Glu Ala Thr Glu Glu Glu Val Met Glu Asn Ala Lys Leu Pro Lys

180

185

190

cat aca gtt ctg aga gct tta tta ttc act ttt aag aaa cag tac ttc 624

His Thr Val Leu Arg Ala Leu Leu Phe Thr Phe Lys Lys Gln Tyr Phe

195

200

205

atg tcg ata gtg ttt gca att ctc gct aat tgt aca tcc ggt ttt aac 672

Met Ser Ile Val Phe Ala Ile Leu Ala Asn Cys Thr Ser Gly Phe Asn

210

215

220

ccc atg att acc aag agg cta att gag ttt gtc gaa gaa aag gct att 720

4

Pro Met Ile Thr Lys Arg Leu Ile Glu Phe Val Glu Glu Lys Ala Ile

225 230 235 240

ttt cat agc atg cat gtt aac aaa ggt att ggt tac gct att ggt gca 768

Phe His Ser Met His Val Asn Lys Gly Ile Gly Tyr Ala Ile Gly Ala

245 250 255

tgt ttg atg atg ttc gtt aac ggg ttg acg ttc aac cat ttc ttt cat 816

Cys Leu Met Met Phe Val Asn Gly Leu Thr Phe Asn His Phe Phe His

260 265 270

aca tcc caa ctg act ggt gtg caa gct aag tct att ctt act aaa gct 864

Thr Ser Gln Leu Thr Gly Val Gln Ala Lys Ser Ile Leu Thr Lys Ala

275 280 285

gcc atg aag aaa atg ttt aat gca tct aat tat gcg aga cat tgt ttt 912

Ala Met Lys Lys Met Phe Asn Ala Ser Asn Tyr Ala Arg His Cys Phe

290 295 300

cct aac ggt aaa gtg act tct ttt gta aca aca gat ctc gct aga att 960

Pro Asn Gly Lys Val Thr Ser Phe Val Thr Thr Asp Leu Ala Arg Ile

305 310 315 320

gaa ttt gcc tta tct ttt cag ccg ttt ttg gct ggg ttc cct gca att 1008

Glu Phe Ala Leu Ser Phe Gln Pro Phe Leu Ala Gly Phe Pro Ala Ile

325 330 335

ttg gct att tgc att gtt tta ttg atc gtt aac ctt gga ccc att gcc 1056

Leu Ala Ile Cys Ile Val Leu Leu Ile Val Asn Leu Gly Pro Ile Ala

340 345 350

tta gtt ggg att ggt att ttt ttc ggt ggg ttt ttc ata tcc tta ttt 1104
Leu Val Gly Ile Gly Ile Phe Phe Gly Gly Phe Phe Ile Ser Leu Phe

355 360 365

gca ttt aag tta att ctg ggc ttt aga att gct gcg aac atc ttc act 1152
Ala Phe Lys Leu Ile Leu Gly Phe Arg Ile Ala Ala Asn Ile Phe Thr

370 375 380

gat gct aga gtt acc atg atg aga gaa gtg ctg aat aat ata aaa atg 1200
Asp Ala Arg Val Thr Met Met Arg Glu Val Leu Asn Asn Ile Lys Met

385 390 395 400

att aaa tat tat acg tgg gag gat gcg tat gaa aaa aat att caa gat 1248
Ile Lys Tyr Tyr Thr Trp Glu Asp Ala Tyr Glu Lys Asn Ile Gln Asp

405 410 415

att agg acc aaa gag att tct aaa gtt aga aaa atg caa cta tca aga 1296
Ile Arg Thr Lys Glu Ile Ser Lys Val Arg Lys Met Gln Leu Ser Arg

420 425 430

aat ttc ttg att gct atg gcc atg tct ttg cct agt att gct tca ttg 1344
Asn Phe Leu Ile Ala Met Ala Met Ser Leu Pro Ser Ile Ala Ser Leu

435 440 445

gtc act ttc ctt gca atg tac aaa gtt aat aaa gga ggc agg caa cct 1392
Val Thr Phe Leu Ala Met Tyr Lys Val Asn Lys Gly Gly Arg Gln Pro

450 455 460

ggt aat att ttt gcc tct tta tct tta ttt cag gtc ttg agt ttg caa 1440
Gly Asn Ile Phe Ala Ser Leu Ser Leu Phe Gln Val Leu Ser Leu Gln
465 470 475 480

atg ttt ttc tta cct att gct att ggt act gga att gac atg atc att 1488
Met Phe Phe Leu Pro Ile Ala Ile Gly Thr Gly Ile Asp Met Ile Ile
485 490 495

gga ttg ggc cgt ttg caa agc tta ttg gag gct cca gaa gat gat cca 1536
Gly Leu Gly Arg Leu Gln Ser Leu Leu Glu Ala Pro Glu Asp Asp Pro
500 505 510

aat cag atg att gaa atg aag cct tct cct ggc ttt gat cca aaa ttg 1584
Asn Gln Met Ile Glu Met Lys Pro Ser Pro Gly Phe Asp Pro Lys Leu
515 520 525

gct tta aaa atg aca cat tgc tca ttt gag tgg gaa gat tat gaa tta 1632
Ala Leu Lys Met Thr His Cys Ser Phe Glu Trp Glu Asp Tyr Glu Leu
530 535 540

aac gac gct att gaa gaa gca aaa gga gaa gct aaa gat gaa ggt aaa 1680
Asn Asp Ala Ile Glu Glu Ala Lys Gly Glu Ala Lys Asp Glu Gly Lys
545 550 555 560

aag aac aaa aaa aag cgt aag gat aca tgg ggt aag cca tct gca agt 1728
Lys Asn Lys Lys Lys Arg Lys Asp Thr Trp Gly Lys Pro Ser Ala Ser
565 570 575

7

act aat aag gcg aaa aga ttg gac aat atg ttg aaa gac aga gac ggc 1776

Thr Asn Lys Ala Lys Arg Leu Asp Asn Met Leu Lys Asp Arg Asp Gly

580

585

590

ccg gaa gat tta gaa aaa act tcg ttt agg ggt ttc aag gac ttg aac 1824

Pro Glu Asp Leu Glu Lys Thr Ser Phe Arg Gly Phe Lys Asp Leu Asn

595

600

605

ttc gat att aaa aag ggc gaa ttt att atg att acg gga cct att ggt 1872

Phe Asp Ile Lys Lys Gly Glu Phe Ile Met Ile Thr Gly Pro Ile Gly

610

615

620

act ggt aaa tct tca tta ttg aat gcg atg gca gga tca atg aga aaa 1920

Thr Gly Lys Ser Ser Leu Leu Asn Ala Met Ala Gly Ser Met Arg Lys

625

630

635

640

act gat ggt aag gtt gaa gtc aac ggg gac tta tta atg tgt ggt tat 1968

Thr Asp Gly Lys Val Glu Val Asn Gly Asp Leu Leu Met Cys Gly Tyr

645

650

655

cca tgg att caa aat gca tct gta aga gat aac atc ata ttc ggt tca 2016

Pro Trp Ile Gln Asn Ala Ser Val Arg Asp Asn Ile Ile Phe Gly Ser

660

665

670

cca ttc aat aaa gaa aag tat gat gaa gta gtt cgt gtt tgc tct ttg 2064

Pro Phe Asn Lys Glu Lys Tyr Asp Glu Val Val Arg Val Cys Ser Leu

675

680

685

aaa gct gat ctg gat att tta ccg gca ggc gat atg acc gaa att ggg 2112

8

Lys Ala Asp Leu Asp Ile Leu Pro Ala Gly Asp Met Thr Glu Ile Gly

690

695

700

gaa cgt ggt att act tta tct ggt ggt caa aag gca cgt atc aat tta 2160

Glu Arg Gly Ile Thr Leu Ser Gly Gly Gln Lys Ala Arg Ile Asn Leu

705

710

715

720

gcc agg tct gtt tat aag aag aag gat att tat cta ttc gac gat gtc 2208

Ala Arg Ser Val Tyr Lys Lys Lys Asp Ile Tyr Leu Phe Asp Asp Val

725

730

735

cta agt gct gtc gat tct cgt gtt ggt aaa cac atc atg gat gaa tgt 2256

Leu Ser Ala Val Asp Ser Arg Val Gly Lys His Ile Met Asp Glu Cys

740

745

750

cta acc gga atg ctt gct aat aaa acc aga att tta gca acg cat caa 2304

Leu Thr Gly Met Leu Ala Asn Lys Thr Arg Ile Leu Ala Thr His Gln

755

760

765

ttg tca ctg att gag aga gct tct aga gtc atc gtt tta ggt act gat 2352

Leu Ser Leu Ile Glu Arg Ala Ser Arg Val Ile Val Leu Gly Thr Asp

770

775

780

ggc caa gtc gat att ggt act gtt gat gag cta aaa gct cgt aat caa 2400

Gly Gln Val Asp Ile Gly Thr Val Asp Glu Leu Lys Ala Arg Asn Gln

785

790

795

800

act ttg ata aat ctt tta caa ttc tct tct caa aat tcg gag aaa gag 2448

Thr Leu Ile Asn Leu Leu Gln Phe Ser Ser Gln Asn Ser Glu Lys Glu

805

810

815

gat gaa gaa cag gaa gcg gtt gtt gcc ggt gaa ttg gga caa cta aaa 2496

Asp Glu Glu Gln Glu Ala Val Val Ala Gly Glu Leu Gly Gln Leu Lys

820

825

830

tat gaa tca gag gta aag gaa ttg act gaa ctg aag aaa aag gct aca 2544

Tyr Glu Ser Glu Val Lys Glu Leu Thr Glu Leu Lys Lys Lys Ala Thr

835

840

845

gaa atg tca caa act gca aat agt ggt aaa att gta gcg gat ggt cat 2592

Glu Met Ser Gln Thr Ala Asn Ser Gly Lys Ile Val Ala Asp Gly His

850

855

860

act agt agt aaa gaa gaa aga gca gtc aat agt atc agt ctg aaa ata 2640

Thr Ser Ser Lys Glu Glu Arg Ala Val Asn Ser Ile Ser Leu Lys Ile

865

870

875

880

tac cgt gaa tac att aaa gct gca gta ggt aag tgg ggt ttt atc gca 2688

Tyr Arg Glu Tyr Ile Lys Ala Ala Val Gly Lys Trp Gly Phe Ile Ala

885

890

895

cta ccg ttg tat gca att tta gtc gtt gga acc aca ttc tgc tca ctt 2736

Leu Pro Leu Tyr Ala Ile Leu Val Val Gly Thr Thr Phe Cys Ser Leu

900

905

910

ttt tct tcc gtt tgg tta tct tac tgg act gag aat aaa ttc aaa aac 2784

Phe Ser Ser Val Trp Leu Ser Tyr Trp Thr Glu Asn Lys Phe Lys Asn

915

920

925

aga cca ccc agt ttt tat atg ggt ctt tac tcc ttc ttt gtg ttt gct 2832

Arg Pro Pro Ser Phe Tyr Met Gly Leu Tyr Ser Phe Phe Val Phe Ala

930

935

940

gct ttc ata ttc atg aat ggc cag ttc acc ata ctt tgc gca atg ggt 2880

Ala Phe Ile Phe Met Asn Gly Gln Phe Thr Ile Leu Cys Ala Met Gly

945

950

955

960

att atg gca tcg aaa tgg tta aat ttg agg gct gtg aaa aga att tta 2928

Ile Met Ala Ser Lys Trp Leu Asn Leu Arg Ala Val Lys Arg Ile Leu

965

970

975

cac act cca atg tca tac ata gat acc aca cct ttg gga cgt att ctg 2976

His Thr Pro Met Ser Tyr Ile Asp Thr Thr Pro Leu Gly Arg Ile Leu

980

985

990

aac aga ttc aca aaa gat aca gat agc tta gat aat gag tta acc gaa 3024

Asn Arg Phe Thr Lys Asp Thr Asp Ser Leu Asp Asn Glu Leu Thr Glu

995

1000

1005

agt tta cgg ttg atg aca tct caa ttt gct aat att gta ggt gtt tgc 3072

Ser Leu Arg Leu Met Thr Ser Gln Phe Ala Asn Ile Val Gly Val Cys

1010

1015

1020

gtc atg tgt att gtt tac ttg ccg tgg ttt gct atc gca att ccg ttt 3120

Val Met Cys Ile Val Tyr Leu Pro Trp Phe Ala Ile Ala Ile Pro Phe

1025

1030

1035

1040

11

ctt ttg gtc atc ttt gtt ctg att gct gat cat tat cag agt tct ggt 3168

Leu Leu Val Ile Phe Val Leu Ile Ala Asp His Tyr Gln Ser Ser Gly

1045

1050

1055

aga gaa att aaa aga ctt gaa gct gtg caa cgg tct ttt gtt tac aat 3216

Arg Glu Ile Lys Arg Leu Glu Ala Val Gln Arg Ser Phe Val Tyr Asn

1060

1065

1070

aat tta aat gaa gtt ttg ggt ggg atg gat aca atc aaa gca tac cga 3264

Asn Leu Asn Glu Val Leu Gly Gly Met Asp Thr Ile Lys Ala Tyr Arg

1075

1080

1085

agt cag gaa cga ttt ttg gcg aaa tca gat ttt ttg atc aac aag atg 3312

Ser Gln Glu Arg Phe Leu Ala Lys Ser Asp Phe Leu Ile Asn Lys Met

1090

1095

1100

aat gag gcg gga tac ctt gta gtt gtc ctg caa aga tgg gta ggt att 3360

Asn Glu Ala Gly Tyr Leu Val Val Val Leu Gln Arg Trp Val Gly Ile

1105

1110

1115

1120

ttc ctt gat atg gtt gct atc gca ttt gca cta att att acg tta ttg 3408

Phe Leu Asp Met Val Ala Ile Ala Phe Ala Leu Ile Ile Thr Leu Leu

1125

1130

1135

tgt gtt acg aga gcc ttt cct att tcc gcg gct tca gtt ggt gtt ttg 3456

Cys Val Thr Arg Ala Phe Pro Ile Ser Ala Ala Ser Val Gly Val Leu

1140

1145

1150

ttg act tat gta tta caa ttg cct ggt cta tta aat acc att tta agg 3504

12

Leu Thr Tyr Val Leu Gln Leu Pro Gly Leu Leu Asn Thr Ile Leu Arg

1155

1160

1165

gca atg act caa aca gag aat gac atg aat agt gcc gaa aga ttg gta 3552

Ala Met Thr Gln Thr Glu Asn Asp Met Asn Ser Ala Glu Arg Leu Val

1170

1175

1180

aca tat gca act gaa cta cca cta gag gca tcc tat aga aag ccc gaa 3600

Thr Tyr Ala Thr Glu Leu Pro Leu Glu Ala Ser Tyr Arg Lys Pro Glu

1185

1190

1195

1200

atg aca cct cca gag tca tgg ccc tca atg ggc gaa ata att ttt gaa 3648

Met Thr Pro Pro Glu Ser Trp Pro Ser Met Gly Glu Ile Ile Phe Glu

1205

1210

1215

aat gtt gat ttt gcc tat aga cct ggt tta cct ata gtt tta aaa aat 3696

Asn Val Asp Phe Ala Tyr Arg Pro Gly Leu Pro Ile Val Leu Lys Asn

1220

1225

1230

ctt aac ttg aat atc aag agt ggg gaa aaa att ggt atc tgt ggt cgt 3744

Leu Asn Leu Asn Ile Lys Ser Gly Glu Lys Ile Gly Ile Cys Gly Arg

1235

1240

1245

aca ggt gct ggt aag tcc act att atg agt gcc ctt tac agg ttg aat 3792

Thr Gly Ala Gly Lys Ser Thr Ile Met Ser Ala Leu Tyr Arg Leu Asn

1250

1255

1260

gaa ttg acc gca ggt aaa att tta att gac aat gtt gat ata agt cag 3840

Glu Leu Thr Ala Gly Lys Ile Leu Ile Asp Asn Val Asp Ile Ser Gln

13

1265

1270

1275

1280

ctg gga ctt ttc gat tta aga aga aaa tta gcc atc att cca caa gat 3888

Leu Gly Leu Phe Asp Leu Arg Arg Lys Leu Ala Ile Ile Pro Gln Asp

1285

1290

1295

cca gta tta ttt agg ggt acg att cgc aag aac tta gat cca ttt aat 3936

Pro Val Leu Phe Arg Gly Thr Ile Arg Lys Asn Leu Asp Pro Phe Asn

1300

1305

1310

gag cgt aca gat gac gaa tta tgg gat gca ttg gtg aga ggt ggt gct 3984

Glu Arg Thr Asp Asp Glu Leu Trp Asp Ala Leu Val Arg Gly Gly Ala

1315

1320

1325

atc gcc aag gat gac ttg ccg gaa gtg aaa ttg caa aaa cct gat gaa 4032

Ile Ala Lys Asp Asp Leu Pro Glu Val Lys Leu Gln Lys Pro Asp Glu

1330

1335

1340

aat ggt act cat ggt aaa atg cat aag ttc cat tta gat caa gca gtg 4080

Asn Gly Thr His Gly Lys Met His Lys Phe His Leu Asp Gln Ala Val

1345

1350

1355

1360

gaa gaa gag ggc tcc aat ttc tcc tta ggt gag aga caa cta tta gca 4128

Glu Glu Glu Gly Ser Asn Phe Ser Leu Gly Glu Arg Gln Leu Leu Ala

1365

1370

1375

tta aca agg gca ttg gtc cgc caa tca aaa ata ttg att ttg gat gag 4176

Leu Thr Arg Ala Leu Val Arg Gln Ser Lys Ile Leu Ile Leu Asp Glu

1380

1385

1390

14

gct aca tcc tca gtg gac tac gaa acg gat ggc aaa atc caa aca cgt 4224

Ala Thr Ser Ser Val Asp Tyr Glu Thr Asp Gly Lys Ile Gln Thr Arg

1395

1400

1405

att gtt gag gaa ttt gga gat tgt aca att ttg tgt att gct cac aga 4272

Ile Val Glu Glu Phe Gly Asp Cys Thr Ile Leu Cys Ile Ala His Arg

1410

1415

1420

ctg aag acc att gta aat tat gat cgt att ctt gtt tta gag aag ggt 4320

Leu Lys Thr Ile Val Asn Tyr Asp Arg Ile Leu Val Leu Glu Lys Gly

1425

1430

1435

1440

gaa gtc gca gaa ttc gat aca cca tgg acg ttg ttt agt caa gaa gat 4368

Glu Val Ala Glu Phe Asp Thr Pro Trp Thr Leu Phe Ser Gln Glu Asp

1445

1450

1455

agt att ttc aga agc atg tgt tct aga tct ggt att gtg gaa aat gat 4416

Ser Ile Phe Arg Ser Met Cys Ser Arg Ser Gly Ile Val Glu Asn Asp

1460

1465

1470

ttc gag aac aga agt taa

4434

Phe Glu Asn Arg Ser

1475

<210> 2

<211> 1477

<212> PRT

15

<213> Saccharomyces cerevisiae

<400> 2

Met Thr Ile Thr Val Gly Asp Ala Val Ser Glu Thr Glu Leu Glu Asn

1

5

10

15

Lys Ser Gln Asn Val Val Leu Ser Pro Lys Ala Ser Ala Ser Ser Asp

20

25

30

Ile Ser Thr Asp Val Asp Lys Asp Thr Ser Ser Ser Trp Asp Asp Lys

35

40

45

Ser Leu Leu Pro Thr Gly Glu Tyr Ile Val Asp Arg Asn Lys Pro Gln

50

55

60

Thr Tyr Leu Asn Ser Asp Asp Ile Glu Lys Val Thr Glu Ser Asp Ile

65

70

75

80

Phe Pro Gln Lys Arg Leu Phe Ser Phe Leu His Ser Lys Lys Ile Pro

85

90

95

Glu Val Pro Gln Thr Asp Asp Glu Arg Lys Ile Tyr Pro Leu Phe His

100

105

110

Thr Asn Ile Ile Ser Asn Met Phe Phe Trp Trp Val Leu Pro Ile Leu

115

120

125

Arg Val Gly Tyr Lys Arg Thr Ile Gln Pro Asn Asp Leu Phe Lys Met

130

135

140

16

Asp Pro Arg Met Ser Ile Glu Thr Leu Tyr Asp Asp Phe Glu Lys Asn

145 150 155 160

Met Ile Tyr Tyr Phe Glu Lys Thr Arg Lys Lys Tyr Arg Lys Arg His

165 170 175

Pro Glu Ala Thr Glu Glu Glu Val Met Glu Asn Ala Lys Leu Pro Lys

180 185 190

His Thr Val Leu Arg Ala Leu Leu Phe Thr Phe Lys Lys Gln Tyr Phe

195 200 205

Met Ser Ile Val Phe Ala Ile Leu Ala Asn Cys Thr Ser Gly Phe Asn

210 215 220

Pro Met Ile Thr Lys Arg Leu Ile Glu Phe Val Glu Glu Lys Ala Ile

225 230 235 240

Phe His Ser Met His Val Asn Lys Gly Ile Gly Tyr Ala Ile Gly Ala

245 250 255

Cys Leu Met Met Phe Val Asn Gly Leu Thr Phe Asn His Phe Phe His

260 265 270

Thr Ser Gln Leu Thr Gly Val Gln Ala Lys Ser Ile Leu Thr Lys Ala

275 280 285

Ala Met Lys Lys Met Phe Asn Ala Ser Asn Tyr Ala Arg His Cys Phe

17

290

295

300

Pro Asn Gly Lys Val Thr Ser Phe Val Thr Thr Asp Leu Ala Arg Ile

305

310

315

320

Glu Phe Ala Leu Ser Phe Gln Pro Phe Leu Ala Gly Phe Pro Ala Ile

325

330

335

Leu Ala Ile Cys Ile Val Leu Leu Ile Val Asn Leu Gly Pro Ile Ala

340

345

350

Leu Val Gly Ile Gly Ile Phe Phe Gly Gly Phe Phe Ile Ser Leu Phe

355

360

365

Ala Phe Lys Leu Ile Leu Gly Phe Arg Ile Ala Ala Asn Ile Phe Thr

370

375

380

Asp Ala Arg Val Thr Met Met Arg Glu Val Leu Asn Asn Ile Lys Met

385

390

395

400

Ile Lys Tyr Tyr Thr Trp Glu Asp Ala Tyr Glu Lys Asn Ile Gln Asp

405

410

415

Ile Arg Thr Lys Glu Ile Ser Lys Val Arg Lys Met Gln Leu Ser Arg

420

425

430

Asn Phe Leu Ile Ala Met Ala Met Ser Leu Pro Ser Ile Ala Ser Leu

435

440

445

18

Val Thr Phe Leu Ala Met Tyr Lys Val Asn Lys Gly Gly Arg Gln Pro

450

455

460

Gly Asn Ile Phe Ala Ser Leu Ser Leu Phe Gln Val Leu Ser Leu Gln

465

470

475

480

Met Phe Phe Leu Pro Ile Ala Ile Gly Thr Gly Ile Asp Met Ile Ile

485

490

495

Gly Leu Gly Arg Leu Gln Ser Leu Leu Glu Ala Pro Glu Asp Asp Pro

500

505

510

Asn Gln Met Ile Glu Met Lys Pro Ser Pro Gly Phe Asp Pro Lys Leu

515

520

525

Ala Leu Lys Met Thr His Cys Ser Phe Glu Trp Glu Asp Tyr Glu Leu

530

535

540

Asn Asp Ala Ile Glu Glu Ala Lys Gly Glu Ala Lys Asp Glu Gly Lys

545

550

555

560

Lys Asn Lys Lys Lys Arg Lys Asp Thr Trp Gly Lys Pro Ser Ala Ser

565

570

575

Thr Asn Lys Ala Lys Arg Leu Asp Asn Met Leu Lys Asp Arg Asp Gly

580

585

590

Pro Glu Asp Leu Glu Lys Thr Ser Phe Arg Gly Phe Lys Asp Leu Asn

595

600

605

Phe Asp Ile Lys Lys Gly Glu Phe Ile Met Ile Thr Gly Pro Ile Gly

610

615

620

Thr Gly Lys Ser Ser Leu Leu Asn Ala Met Ala Gly Ser Met Arg Lys

625

630

635

640

Thr Asp Gly Lys Val Glu Val Asn Gly Asp Leu Leu Met Cys Gly Tyr

645

650

655

Pro Trp Ile Gln Asn Ala Ser Val Arg Asp Asn Ile Ile Phe Gly Ser

660

665

670

Pro Phe Asn Lys Glu Lys Tyr Asp Glu Val Val Arg Val Cys Ser Leu

675

680

685

Lys Ala Asp Leu Asp Ile Leu Pro Ala Gly Asp Met Thr Glu Ile Gly

690

695

700

Glu Arg Gly Ile Thr Leu Ser Gly Gly Gln Lys Ala Arg Ile Asn Leu

705

710

715

720

Ala Arg Ser Val Tyr Lys Lys Lys Asp Ile Tyr Leu Phe Asp Asp Val

725

730

735

Leu Ser Ala Val Asp Ser Arg Val Gly Lys His Ile Met Asp Glu Cys

740

745

750

Leu Thr Gly Met Leu Ala Asn Lys Thr Arg Ile Leu Ala Thr His Gln

20

755

760

765

Leu Ser Leu Ile Glu Arg Ala Ser Arg Val Ile Val Leu Gly Thr Asp

770

775

780

Gly Gln Val Asp Ile Gly Thr Val Asp Glu Leu Lys Ala Arg Asn Gln

785

790

795

800

Thr Leu Ile Asn Leu Leu Gln Phe Ser Ser Gln Asn Ser Glu Lys Glu

805

810

815

Asp Glu Glu Gln Glu Ala Val Val Ala Gly Glu Leu Gly Gln Leu Lys

820

825

830

Tyr Glu Ser Glu Val Lys Glu Leu Thr Glu Leu Lys Lys Lys Ala Thr

835

840

845

Glu Met Ser Gln Thr Ala Asn Ser Gly Lys Ile Val Ala Asp Gly His

850

855

860

Thr Ser Ser Lys Glu Glu Arg Ala Val Asn Ser Ile Ser Leu Lys Ile

865

870

875

880

Tyr Arg Glu Tyr Ile Lys Ala Ala Val Gly Lys Trp Gly Phe Ile Ala

885

890

895

Leu Pro Leu Tyr Ala Ile Leu Val Val Gly Thr Thr Phe Cys Ser Leu

900

905

910

21

Phe Ser Ser Val Trp Leu Ser Tyr Trp Thr Glu Asn Lys Phe Lys Asn

915

920

925

Arg Pro Pro Ser Phe Tyr Met Gly Leu Tyr Ser Phe Phe Val Phe Ala

930

935

940

Ala Phe Ile Phe Met Asn Gly Gln Phe Thr Ile Leu Cys Ala Met Gly

945

950

955

960

Ile Met Ala Ser Lys Trp Leu Asn Leu Arg Ala Val Lys Arg Ile Leu

965

970

975

His Thr Pro Met Ser Tyr Ile Asp Thr Thr Pro Leu Gly Arg Ile Leu

980

985

990

Asn Arg Phe Thr Lys Asp Thr Asp Ser Leu Asp Asn Glu Leu Thr Glu

995

1000

1005

Ser Leu Arg Leu Met Thr Ser Gln Phe Ala Asn Ile Val Gly Val Cys

1010

1015

1020

Val Met Cys Ile Val Tyr Leu Pro Trp Phe Ala Ile Ala Ile Pro Phe

1025

1030

1035

1040

Leu Leu Val Ile Phe Val Leu Ile Ala Asp His Tyr Gln Ser Ser Gly

1045

1050

1055

Arg Glu Ile Lys Arg Leu Glu Ala Val Gln Arg Ser Phe Val Tyr Asn

1060

1065

1070

Asn Leu Asn Glu Val Leu Gly Gly Met Asp Thr Ile Lys Ala Tyr Arg
1075 1080 1085

Ser Gln Glu Arg Phe Leu Ala Lys Ser Asp Phe Leu Ile Asn Lys Met
1090 1095 1100

Asn Glu Ala Gly Tyr Leu Val Val Val Leu Gln Arg Trp Val Gly Ile
1105 1110 1115 1120

Phe Leu Asp Met Val Ala Ile Ala Phe Ala Leu Ile Ile Thr Leu Leu
1125 1130 1135

Cys Val Thr Arg Ala Phe Pro Ile Ser Ala Ala Ser Val Gly Val Leu
1140 1145 1150

Leu Thr Tyr Val Leu Gln Leu Pro Gly Leu Leu Asn Thr Ile Leu Arg
1155 1160 1165

Ala Met Thr Gln Thr Glu Asn Asp Met Asn Ser Ala Glu Arg Leu Val
1170 1175 1180

Thr Tyr Ala Thr Glu Leu Pro Leu Glu Ala Ser Tyr Arg Lys Pro Glu
1185 1190 1195 1200

Met Thr Pro Pro Glu Ser Trp Pro Ser Met Gly Glu Ile Ile Phe Glu
1205 1210 1215

Asn Val Asp Phe Ala Tyr Arg Pro Gly Leu Pro Ile Val Leu Lys Asn

23

1220

1225

1230

Leu Asn Leu Asn Ile Lys Ser Gly Glu Lys Ile Gly Ile Cys Gly Arg

1235

1240

1245

Thr Gly Ala Gly Lys Ser Thr Ile Met Ser Ala Leu Tyr Arg Leu Asn

1250

1255

1260

Glu Leu Thr Ala Gly Lys Ile Leu Ile Asp Asn Val Asp Ile Ser Gln

265

1270

1275

1280

Leu Gly Leu Phe Asp Leu Arg Arg Lys Leu Ala Ile Ile Pro Gln Asp

1285

1290

1295

Pro Val Leu Phe Arg Gly Thr Ile Arg Lys Asn Leu Asp Pro Phe Asn

1300

1305

1310

Glu Arg Thr Asp Asp Glu Leu Trp Asp Ala Leu Val Arg Gly Gly Ala

1315

1320

1325

Ile Ala Lys Asp Asp Leu Pro Glu Val Lys Leu Gln Lys Pro Asp Glu

1330

1335

1340

Asn Gly Thr His Gly Lys Met His Lys Phe His Leu Asp Gln Ala Val

345

1350

1355

1360

Glu Glu Glu Gly Ser Asn Phe Ser Leu Gly Glu Arg Gln Leu Leu Ala

1365

1370

1375

24

Leu Thr Arg Ala Leu Val Arg Gln Ser Lys Ile Leu Ile Leu Asp Glu

1380

1385

1390

Ala Thr Ser Ser Val Asp Tyr Glu Thr Asp Gly Lys Ile Gln Thr Arg

1395

1400

1405

Ile Val Glu Glu Phe Gly Asp Cys Thr Ile Leu Cys Ile Ala His Arg

1410

1415

1420

Leu Lys Thr Ile Val Asn Tyr Asp Arg Ile Leu Val Leu Glu Lys Gly

425

1430

1435

1440

Glu Val Ala Glu Phe Asp Thr Pro Trp Thr Leu Phe Ser Gln Glu Asp

1445

1450

1455

Ser Ile Phe Arg Ser Met Cys Ser Arg Ser Gly Ile Val Glu Asn Asp

1460

1465

1470

Phe Glu Asn Arg Ser

1475

INTERNATIONAL SEARCH REPORT

Int. Patent Application No.
PCT/US 98/17546

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/82 C12N15/31 A01H5/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N A01H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LU, Y.-P., ET AL.: "AtMRP1 gene of Arabidopsis encodes a glutathione S-conjugate pump: Isolation and functional definition of a plant ATP-binding cassette transporter gene" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 94, 22 July 1997, pages 8243-8248, XP002083621 WASHINGTON US see the whole document	1
P, X	WO 98 21938 A (UNIV PENNSYLVANIA) 28 May 1998 see page 90 - page 91; claims 1-26; figures 13-18	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Z" document member of the same patent family

Date of the actual completion of the international search

9 November 1998

Date of mailing of the international search report

24/11/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3018

Authorized officer

Maddox, A

INTERNATIONAL SEARCH REPORT

Int lional Application No
PCT/US 98/17546

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	VOET, M., ET AL.: "S. cerevisiae chromosome VII reading frame ORF YGR281w" EMBL SEQUENCE ACCESSION NO. Z73066, 17 May 1996, XP002083622	1
A	KATZMANN, D.J., ET AL.: "Oligomycin resistance ATP-dependent permease YOR1" SWISS-PROT ACCESSION NO. P53049, 1 October 1996, XP002083623 see the whole document	1
A	-& KATZMANN, D.J., ET AL.: "Expression of an ATP-binding cassette transporter-encoding gene (YOR1) is required for oligomycin resistance in Saccharomyces cerevisiae" MOLECULAR AND CELLULAR BIOLOGY, vol. 15, no. 12, December 1995, pages 6875-6883, XP002083629 see the whole document	1
A	WO 96 06175 A (PIONEER HI BRED INT) 29 February 1996 see the whole document	1-31
A	WO 96 20595 A (PROGUARD INC ;EMERSON RALPH W (US); CRANDALL BRADFORD G JR (US)) 11 July 1996 see the whole document	1-31
A	WO 95 06128 A (DEKALB GENETICS CORP) 2 March 1995 see page 37, line 25 - page 38, line 8	1-31
A	EP 0 644 262 A (TAKARA SHUZO CO) 22 March 1995 see sequence ID 9	1
A	ANZAI, H., ET AL.: "Transgenic tobacco resistant to a bacterial disease by the detoxification of a pathogenic toxin" MOL. GEN. GENET., vol. 219, 1989, pages 492-494, XP002083624 see the whole document	1-31
A	DE LA FUENTE-MARTINEZ, J.M., ET AL.: "Expression of a bacterial phaseolotoxin resistant ornithyl transcarbamylase in transgenic tobacco confers resistance to Pesudomonas syringae pv. phaseolicola" BIOTECHNOLOGY, vol. 10, August 1992, pages 905-909, XP002083005 see the whole document	1-31
	-/-	

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/US 98/17546

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 92 15685 A (RHONE POULENC AGROCHIMIE) 17 September 1992 see the whole document	1-31
A	WO 94 13790 A (SANOFI ELF ;ELF AQUITAINE (FR); PIGNARD ANNIE (FR); GREZES BESSET) 23 June 1994 see the whole document	1-31
A	WO 95 25114 A (UNIV TENNESSEE RES CORP) 21 September 1995 see page 16 - page 21	1-31
A	WO 94 10303 A (UNIV KINGSTON) 11 May 1994 see the whole document	1-31
A	OW, D.W.: "Phytochelatin-mediated cadmium tolerance in Schizosaccharomyces pombe" IN VITRO CELL DEV BIOL, vol. 29p, October 1993, pages 213-219, XP002083625 see page 218, left-hand column, paragraph 2	1
A	WO 91 06651 A (UNIV KINGSTON) 16 May 1991 see the whole document	1
A	WO 96 34959 A (AUCKLAND UNISERVICES LTD ;GARDNER RICHARD CLAGUE (NZ); MACDIARMID) 7 November 1996 see the whole document	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/17546

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9821938 A	28-05-1998	AU 5451198 A	10-06-1998
WO 9606175 A	29-02-1996	US 5792931 A	11-08-1998
		AU 697831 B	15-10-1998
		AU 3491095 A	14-03-1996
		CA 2195784 A	29-02-1996
		EP 0775211 A	28-05-1997
		US 5716820 A	10-02-1998
		ZA 9506531 A	25-03-1996
WO 9620595 A	11-07-1996	AU 4744296 A	24-07-1996
		BR 9510180 A	14-10-1997
		CA 2208753 A	11-07-1996
		EP 0800345 A	15-10-1997
		PL 321179 A	24-11-1997
WO 9506128 A	02-03-1995	AU 5640498 A	04-06-1998
		AU 684105 B	04-12-1997
		AU 7716994 A	21-03-1995
		BR 9407355 A	19-08-1997
		CA 2170260 A	02-03-1995
		EP 0721509 A	17-07-1996
		HU 74392 A	30-12-1996
		US 5780709 A	14-07-1998
		ZA 9406488 A	30-11-1995
EP 0644262 A	22-03-1995	AU 677387 B	24-04-1997
		AU 6312994 A	01-12-1994
		CA 2124034 A	25-11-1994
		JP 7313172 A	05-12-1995
WO 9215685 A	17-09-1992	FR 2673644 A	11-09-1992
		AU 660976 B	13-07-1995
		AU 1682092 A	06-10-1992
		BG 61275 B	30-04-1997
		BR 9204788 A	27-07-1993
		CA 2082042 A	06-09-1992
		CN 1065683 A	28-10-1992
		CZ 9203369 A	19-01-1994
		EP 0531498 A	17-03-1993

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/17546

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9215685 A		HU 65677 A MX 9200917 A NZ 241829 A PT 100203 A	28-07-1994 01-11-1992 27-04-1994 30-07-1993
WO 9413790 A	23-06-1994	AU 5653294 A CA 2151146 A EP 0672124 A	04-07-1994 23-06-1994 20-09-1995
WO 9525114 A	21-09-1995	US 5689039 A CA 2207851 A EP 0767797 A JP 10500562 T	18-11-1997 21-09-1995 16-04-1997 20-01-1998
WO 9410303 A	11-05-1994	AU 671160 B AU 5173693 A AU 682140 B AU 7177896 A EP 0666911 A JP 8504323 T US 5489519 A US 5766880 A	15-08-1996 24-05-1994 18-09-1997 06-02-1997 16-08-1995 14-05-1996 06-02-1996 16-06-1998
WO 9106651 A	16-05-1991	US 5272085 A AU 6542390 A CA 2070395 A EP 0494246 A JP 5500900 T	21-12-1993 31-05-1991 01-05-1991 15-07-1992 25-02-1993
WO 9634959 A	07-11-1996	AU 5517896 A	21-11-1996

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.